Newsroom
August 9, 2024
This news segment mentions that scientists from The University of Texas Health Science Center at San Antonio led a pilot study showing that the antiretroviral drug lamivudine shows potential for Alzheimer’s disease treatment. Watch Now
August 9, 2024
Andrew Brenner, MD, PhD, professor and chair of neuro-oncology research at the Mays Cancer Center at The University of Texas Health Science Center at San Antonio, and William Kelly, MD, assistant professor, Department of Medicine, Division of Hematology and Oncology, were quoted in this article. Read More
August 9, 2024
Andrew Brenner, MD, PhD, professor and chair of Neuro-Oncology research at the Mays Cancer Center at The University of Texas Health Science Center at San Antonio, and William Kelly, MD, assistant professor, Department of Medicine, Division of Hematology and Oncology, were quoted in this article. Read More
August 9, 2024
Andrew Brenner, MD, PhD, professor and chair of Neuro-Oncology research at the Mays Cancer Center at The University of Texas Health Science Center at San Antonio, and William Kelly, MD, assistant professor, Department of Medicine, Division of Hematology and Oncology, were quoted in this article. Read More
August 8, 2024
A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University of Texas Health Science Center at San Antonio (UT Health San Antonio). The window trial, in which patients agreed to receive a novel […]
June 6, 2024
The Max and Minnie Tomerlin Voelcker Fund recently awarded $800,000 to UT Health San Antonio to support research projects from early career investigators. Voelcker Fund Young Investigator Awards The Voelcker Fund Young Investigator Awards provide each recipient with a total of $350,000 in funding allocated over three years to support emerging researchers conducting biomedical research. […]